Escolar Documentos
Profissional Documentos
Cultura Documentos
Produtos
fitoterápicos de Passiflora para ansiedade: um potencial inexplorado. ScientificWorldJournal. 20 de julho
de 2020; 2020: 6598434.
1. Introdução
ansiedade. No entanto, muitos riscos estão associados ao seu uso, como dependência,
síndrome de abstinência e redução dos reflexos motores. Portanto, o uso e a aceitação
haja evidência de uso seguro contínuo por um período mínimo de trinta anos. Além
disso, eles não podem ser usados para doenças graves; eles não podem conter
1
motivos para a recusa do registro ou autorização de comercialização devem ser
monitoramento.
2.1. Gênero Passiflora (Passifloraceae)
espécies e 400 híbridos artificiais [ 23 ] ou, segundo outros autores, mais de 600
espécies [ 22 , 24 , 25 ]. Pelo menos 140 são nativos do Brasil e 70 deles produzem
sido relatadas para outras espécies brasileiras do mesmo gênero, fornecendo uma
fonte alternativa para a formulação de medicamentos fitoterápicos.
2.2. Constituintes Químicos
2
Em estudos fitoquímicos, alguns trabalhos relataram que os flavonóides e alcalóides
(7) [ 53 , 54 ]. Além disso, os flavonóides livres apigenina (8), luteolina (9), quercetina
(10), caempferol (11) e crisina (12) também são encontrados [ 33 ].figura 1ilustra as
3
2.3. Mecanismo de ação ansiolítica
adicionais revelaram duas novas regiões de repulsivo estérico em torno das regiões 4′ e
5′ do anel B [ 61 , 64 ].
4
sinaptossomas corticais de rato [ 30 , 67 , 69 , 70 ]. O artigo de revisão escrito por
envolvido [ 30 ].
Em um estudo, o caempferol exibiu uma afinidade muito baixa para o local de ligação
quercetina estavam ativos após a administração oral, embora estavam inativos via ip
[ 72 ].
5
por Cook e colaboradores [ 59 , 60 ], permitindo o reconhecimento de um sítio
Francesa recomendam pelo menos 1,5% dos flavonóides expressos como vitexina
[ 78 ].
ponto, a extração acelerada com solvente pode ser usada para obter extratos
enriquecidos em compostos polifenólicos de diferentes espécies
6
algumas técnicas que podem ser combinadas e aplicadas no desenvolvimento de
identificação da substância ativa costuma ser difícil, e esse fato pode comprometer o
conhecimento das propriedades do ADMET no organismo [ 80 , 82 ].
absorção pelo intestino humano e efeitos colaterais na absorção através da BBB para
iso-orientina, isovitexina e luteolina. A apigenina e o kaempferol mostraram valores
positivos para BBB e HIA [ 80 , 83 , 85 ]. A importância de uma substância que atravessa
7
a BBB está parcialmente relacionada à atividade biológica necessária, e isso é baseado
[ 80 , 86 , 87 ].
entre elas, carcinógenos, ácidos graxos, ácidos biliares e esteroides, o que evidencia sua
importância na caracterização das propriedades metabólicas de várias
eram não substratos para todos os substratos do CYP450 (2C9, 2D6), e a maioria deles
inibiu a maioria dos inibidores do CYP450 (2C9 e 2D6) [ 80 , 83 , 85 ]. A inibição das
eficácia. O estudo mais completo é descrito por Mori e colegas [ 91 ], que foi avaliado
8
por The Cochrane Collaboration [ 92 ] e EMA [ 21 ]. De acordo com essas avaliações, o
9
com midazolam. Os autores descobriram que P. incarnata mostrou um efeito ansiolítico
semelhante ao midazolam.
5,2% da qualidade do sono, mas nenhum efeito significativo no tempo total de sono e
despertares noturnos.
aspectos, desde o fornecedor dos princípios ativos até o produto final, produzido sob
rígidas normas sanitárias. A Resolução RDC nº 105, de 31 de agosto de 2016, exige a
10
o P. incarnata foi utilizado em 30 produtos registrados. O registro do uso de
incarnata .
References
1. Carlini E. A. Plants and the central nervous system. Pharmacology Biochemistry and
Behavior. 2003;75:501–512. doi: 10.1016/s0091-3057(03)00112-6. [PubMed] [CrossRef] [Google Scholar]
2. Dhawan K., Kumar S., Sharma A. Comparative anxiolytic activity profile of various preparations
of Passiflora incarnata Linneaus: a comment on medicinal plants’ standardization. Journal of Alternative
and Complementary Medicine. 2002;8(3):283–291. doi: 10.1089/10755530260127970. [PubMed]
[CrossRef] [Google Scholar]
3. Wakdikar S. Global health care challenge: Indian experiences and new prescriptions. Electronic Journal of
Biotechnoly. 2004;7:214–220. doi: 10.2225/vol7-issue3-fulltext-5. [CrossRef] [Google Scholar]
4. Germany, Federal Law Gazette [BGBl] Medicinal products act, part I. 2005;12:p. 3394. Updated by Federal
Law Gazette I, Law of October 19, 2012, p.
2192. http://www.gesetze-im-internet.de/englisch_amg/medicinal_products_act.pdf. [Google Scholar]
7. Miroddi M., Mannucci C., Mancari F., Navarra M., Calapai G. Research and development for botanical
products in medicinals and food supplements market. Evidence-Based Complementary Alternative
Medicine. 2013;2013:6. doi: 10.1155/2013/649720.649720 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
8. Brazil, Ministry of Health. “RDC no 14/March 31, 2010,” Diário Oficial da União. Brasilia, Brazil: ANVISA;
2010. http://portal.anvisa.gov.br/documents/10181/2718376/RDC_14_2010_COMP.pdf/a919c09b-0717-
451d-849b-067153c02930?version=1.0. [Google Scholar]
9. Brazil, Ministry of Health. “RDCN. 26/May 13, 2014,” Diário Oficial da União, Brasilia, Section 1. Brasilia,
Brazil: ANVISA; 2014. pp. 52–58. http://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?
jornal=1&pagina=52&data=14/05/2014. [Google Scholar]
10. Arifin S. F., Al Shami A., Omar S. S. S., Jalil M. A. A., Khalid K. A., Hadi H. Impact of modern technology on
the development of natural-based products. Journal of Ayurvedic and Herbal Medicine. 2019;5:133–
142. [Google Scholar]
13. SciFinder® Bibliographic Database and Search Site. Columbus, OH, USA: Chemical Abstracts Service;
2019. http://scifinder.cas.org/ [Google Scholar]
11
15. United States, Department of Health and Human Services. Database. ClinicalTrials.Gov. Bethesda, MA,
USA: National Institutes of Health (NIH); 2020. https://clinicaltrials.gov. [Google Scholar]
20. MHRA (Medicines and Healthcare Products Regulatory Agency) Guidance: Herbal Medicines Granted a
Traditional Herbal Registration. London UK: Medicines and Healthcare Products Regulatory Agency;
2014. https://www.gov.uk/government/publications/herbal-medicines-granted-a-traditional-herbal-
registration-thr/herbal-medicines-granted-a-traditional-herbal-registration. [Google Scholar]
22. Muschner V. C., Lorenz A. P., Cervi A. C., Bonatto S. L., Souza-Chies T. T. A first molecular phylogenetic
analysis of Passiflora (Passifloraceae) American Journal of Botany. 2003;8:1229–1238.
doi: 10.3732/ajb.90.8.1229. [PubMed] [CrossRef] [Google Scholar]
23. Ulmer T., Mac Dougal J. M. Passiflora: Passionflowers of the World. Portland, OR, USA: Timber Press;
2004. [Google Scholar]
25. Souza M. M., Pereira T. N. S., Vieira M. C. Cytogenetic studies in some species of Passiflora L.
(Passifloraceae): a review emphasizing Brazilian species. Brazilian Archives of Biology
Technology. 2008;51:247–258. doi: 10.1590/s1516-89132008000200003. [CrossRef] [Google Scholar]
26. Cerqueira-Silva C. B. M., Conceição L. D. H. C. S., Souza A. P., Corrêa R. X. A history of passion fruit
woodiness disease with emphasis on the current situation in Brazil and prospects for Brazilian passion fruit
cultivation. European Journal of Plant Pathology. 2014;139:261–270. doi: 10.1007/s10658-014-0391-
z. [CrossRef] [Google Scholar]
27. Gosmann G., Provesnsi G., Comunello L. N., Rates S. M. K. Composição química e aspectos
farmacológicos de espécies de Passiflora L. (Passifloraceae) Revista Brasileira de Biociencias. 2011;9:88–
99. [Google Scholar]
28. Oliveira J. C., Ruggiero C. Espécies de Maracujá com potencial agronômico, In: Faleiro F. G., Junqueira N.
T. V., Braga M. F., editors. Maracujá germoplama e melhoramento genético. Planaltina, Brazil: Embrapa
Cerrados; 2005. pp. 141–158. http://www.cpac.embrapa.br/ivrtpm/homepage/capitulos/cap_6.pdf. [Google
Scholar]
29. Braga A., Medeiros T. P., Araújo B. V. Investigação da atividade antihiperglicemiante da farinha da casca
de Passiflora edulis Sims, Passifloraceae, em ratos diabéticos induzidos por aloxano. Revista Brasileira de
Farmacognosia. 2010;20:186–191. doi: 10.1590/s0102-695x2010000200009. [CrossRef] [Google Scholar]
30. Miroddi M., Calapai G., Navarra M., Minciullo P. L., Gangemi S. Passiflora incarnata L.:
ethnopharmacology, clinical application, safety and evaluation of clinical trials. Journal of
Ethnopharmacology. 2013;150:791–804. doi: 10.1016/j.jep.2013.09.047. [PubMed] [CrossRef] [Google
Scholar]
12
31. Klein N., Gazola A. C., C de Lima T., Schenkel E., Nieber K., Butterweck V. Assessment of sedative effects
of Passiflora edulis f. flavicarpa and Passiflora alata extracts in mice, measured by telemetry. Phytotherapy
Research. 2014;28:706–713. doi: 10.1002/ptr.5043. [PubMed] [CrossRef] [Google Scholar]
32. Cervi A. C., Rodrigues W. A. Nomenclatural and taxonomic review of Passifloraceae species illustrated
and described by Vellozo in Flora Fluminensis. Acta Botanica Brasilica. 2010;24:1109–1111.
doi: 10.1590/s0102-33062010000400029. [CrossRef] [Google Scholar]
33. Dhawan K., Dhawan S., Sharma A. Passiflora: a review update. Journal of Ethnopharmacololy. 2004;94:1–
23. doi: 10.1016/j.jep.2004.02.023. [PubMed] [CrossRef] [Google Scholar]
34. De-Paris F., Petry R. D., Reginatto F. H., et al. Pharmacochemical study of aqueous extract of Passiflora
alata Dryander and Passiflora edulis Sims. Acta Farmaceutica Bonaerense. 2002;21:5–8. [Google Scholar]
35. Soulimani R., Younos C., Jarmouni S., Bousta D., Misslin R., Mortier F. Behavioural effects of Passiflora
incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. Journal of
Ethnopharmacology. 1997;57:11–20. doi: 10.1016/s0378-8741(97)00042-1. [PubMed] [CrossRef] [Google
Scholar]
36. Oliveira M. S., Pinheiro I. O., Silva F. S. B. V. Vermicompost and arbuscular mycorrhizal fungi: an
alternative to increase foliar orientin and vitexin-2-O-ramnoside synthesis in Passiflora alata Curtis
seedlings. Industrial Crops and Products. 2015;77:754–757.
doi: 10.1016/j.indcrop.2015.09.061. [CrossRef] [Google Scholar]
37. Rehwald A., Meier B., Sticher O. Qualitative and quantitative reversed-phase high-performance liquid
chromatography of flavonoids in Passiflora incarnata L. Pharmaceutica Acta Helvetiae. 1994;69:153–158.
doi: 10.1016/0031-6865(94)90017-5. [CrossRef] [Google Scholar]
38. Gomes S. V. F., Portugal L. A., Anjos J. P., et al. Accelerated solvent extraction of phenolic compounds
exploiting a Box-Behnken design and quantification of five flavonoids by HPLC-DAD
in Passiflora species. Microchemical Journal. 2017;132:28–35.
doi: 10.1016/j.microc.2016.12.021. [CrossRef] [Google Scholar]
39. Zucolotto S. M., Fagundes C., Reginatto F. H., et al. Analysis of C-glycosyl flavonoids from south
American Passiflora species by HPLC-DAD and HPLC-MS. Phytochemical Analysis. 2012;23:232–239.
doi: 10.1002/pca.1348. [PubMed] [CrossRef] [Google Scholar]
40. Ulubelen A., Oksuz S., Mabry T. J., Dellamonica G., Chopin J. C-glycosylflavonoids from Passiflora pittieri,
P. alata, P. ambigua and Adenia mannii. Journal of Natural Products. 1982;45:p. 783.
doi: 10.1021/np50024a030. [CrossRef] [Google Scholar]
41. Farag M. A., Otify A., Porzel A., Michel C. G., Elsayed A., Wessjohann L. A. Comparative metabolite
profiling and fingerprinting of genus Passiflora leaves using a multiplex approach of UPLC-NS and NMR
analysed by chemometric tools. Analytical and Bioanalytical Chemistry. 2016;408:3125–3143.
doi: 10.1007/s00216-016-9376-4. [PubMed] [CrossRef] [Google Scholar]
42. Wosch L., Santos K. C., Imig D. C. Comparative study of Passiflora taxa leaves: II. A chromatographic
profile. Brazilian Journal Pharmacognosy. 2017;27:40–49. doi: 10.1016/j.bjp.2016.06.007. [CrossRef] [Google
Scholar]
43. Lin C. L., Kao C. L., Huang S. C., et al. Chemical constituents of fruit shells of Passiflora edulis. Chemistry
Natural Compounds. 2016;52:314–315. doi: 10.1007/s10600-016-1626-3. [CrossRef] [Google Scholar]
44. Hu Y., Jiao L., Jiang M. H., et al. A new C-glycosyl flavone and a new neolignan glycoside from Passiflora
edulis Sims peel. Natural Products Research. 2018;32:2312–2318.
doi: 10.1080/14786419.2017.1410809. [PubMed] [CrossRef] [Google Scholar]
45. Petry R. D., De Souza K. C. B., Bassani V. L., Petrovick P. R., Ortega G. G. Doseamento do teor de
flavonóides totais em extratos em extratos hidroalcóolicos de Passiflora alata Dryander (maracujá) Revista
Brasileira de Farmácia. 1998;79:7–10. [Google Scholar]
13
46. Petry R. D., Reginatto F., De-Paris F., et al. Comparative pharmacological study of hydroethanol extracts
of Passiflora alata and Passiflora edulis leaves. Phytotherapy Research. 2001;15:162–164.
doi: 10.1002/ptr.694. [PubMed] [CrossRef] [Google Scholar]
47. Müller S. D., Vasconcelos S. B., Coelho M., Biavatti M. V. LC and UV determination of flavonoids
from: Passiflora alata medicinal extracts and leaves. Journal of Pharmaceutical and Biomedical
Analysis. 2005;37:399–403. doi: 10.1016/j.jpba.2004.10.047. [PubMed] [CrossRef] [Google Scholar]
48. Pereira C. A. M., Yariwake J. H., Lanças F. M., Wauters J. N., Tits M., Angenot L. A HPTLC densitometric
determination of flavonoids from Passiflora alata, P. edulis, P. incarnata and P. caerulea and comparison
with HPLC method. Phytochemical Analysis. 2004;15:241–248. doi: 10.1002/pca.778. [PubMed]
[CrossRef] [Google Scholar]
49. Reginatto F., De-Paris H. F., Petry R. D., et al. Evaluation of anxiolytic activity of spray dried powders of
two South Brazilian Passiflora species. Phytotherapy Research. 2006;20:348–351.
doi: 10.1002/ptr.1853. [PubMed] [CrossRef] [Google Scholar]
50. Gonzáles Ortega G., Schmidt P. C. Stability studies on dried extracts of passion flower (Passiflora
incarnata L.) Pharma Sciences. 1995;5:385–389. [Google Scholar]
51. Quercia V., Turchetto L., Pierini N., Cuozzo V., Percaccio G. Identification and determination of vitexin
and isovitexin in Passiflora incarnata extracts. Journal of Chromatograph A. 1978;161:396–402.
doi: 10.1016/s0021-9673(01)85261-4. [CrossRef] [Google Scholar]
52. Jay M. C-glycosylflavonoids. In: Harbone J. B., editor. The Flavonoids. London, UK: Chapman & Hall;
1996. [Google Scholar]
53. Wohlmuth H., Penman K. G., Pearson T., Lehmann R. P. Pharmacognosy and chemotypes of
passionflower (Passiflora incarnata L.) Biological and Pharmaceutical Bulletin. 2010;33:1015–1018.
doi: 10.1248/bpb.33.1015. [PubMed] [CrossRef] [Google Scholar]
54. Zeraik M. L., Pereira C. A. M., Zuin V. G., Yariwake J. H., Maracujá Um alimento funcional? Revista
Brasileira de Farmacognosia. 2010;20:459–471. doi: 10.1590/s0102-695x2010000300026. [CrossRef] [Google
Scholar]
57. WHO, Passiflorae H. WHO Monographs on Selected Medicinal Plants. Geneva, Switzerland: World Health
Organization Press; 2007. pp. 257–267. [Google Scholar]
58. Wasowski C., Marder M. Flavonoids as GABAA receptor ligands: the whole story? Journal of Experimental
Pharmacology. 2012;4:9–24. [PMC free article] [PubMed] [Google Scholar]
59. Wang F., Huen M. S. Y., Tsang S. Y., Xue H. Neuroactive flavonoids interacting with GABA A receptor
complex. Current Drug Targets. 2005;4:575–585. doi: 10.2174/156800705774322030. [PubMed]
[CrossRef] [Google Scholar]
60. Zhang W., Koehler K. F., Zhang P., Cook J. M. Development of a comprehensive pharmacophore model
for the benzodiazepine receptor. Drug Design and Discovery. 1995;12:193–248. [PubMed] [Google Scholar]
61. Hanrahan J. R., Chebib M., Johnston G. A. R. Flavonoid modulation of GABA A receptors. British Journal of
Pharmacology. 2011;163:234–245. doi: 10.1111/j.1476-5381.2011.01228.x. [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
62. Dekermendjian K., Kahnberg P., Witt M. R., Sterner O., Nielsen M., Liljefors T. Structure–activity
relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat
brain GABAA receptor complex. Journal of Medicinal Chemistry. 1999;42:4343–4350.
doi: 10.1021/jm991010h. [PubMed] [CrossRef] [Google Scholar]
14
63. Huang X., Liu T., Gu J., et al. 3D-QSAR Model of flavonoids binding at benzodiazepine site in
GABAA receptors. Journal of Medicinal Chemistry. 2001;44:1883–1891. doi: 10.1021/jm000557p. [PubMed]
[CrossRef] [Google Scholar]
64. Kahnberg P., Lager E., Rosenberg C., et al. Refinement and evaluation of a pharmacophore model for
flavone derivatives binding to the benzodiazepine site of the GABA A receptor. Journal of Medicinal
Chemistry. 2002;45:4188–4201. doi: 10.1021/jm020839k. [PubMed] [CrossRef] [Google Scholar]
65. Holanda D. K. R., Wurlitzer N. J., Dionisio A. P., et al. Garlic passion fruit (Passiflora tenuifila Killip):
assessment of eventual acute toxicity, anxiolytic, sedative, and anticonvulsant effects using in
vivo assays. Food Research International. 2020;128 doi: 10.1016/j.foodres.2019.108813.108813 [PubMed]
[CrossRef] [Google Scholar]
66. Zhang J., He Y., Jiang X., Jiang H., Shen J. Nature brings new avenues to the therapy of central nervous
system diseases-an overview of possible treatments derived from natural products. Science China Life
Sciences. 2019;62(10):1332–1367. doi: 10.1007/s11427-019-9587-y. [PubMed] [CrossRef] [Google Scholar]
67. Germán-Ponciano L. J., Puga-Olguín A., Rovirosa-Hernández M. J., Caba M., Meza E., Rodríguez-Landa J.
F. Differential effects of acute and chronic treatment with the flavonoid chrysin on anxiety-like behavior
and fos immunoreactivity in the lateral septal nucleus in rat. Acta Pharmaceutica. 2020;70:387–397.
doi: 10.2478/acph-2020-0022. [PubMed] [CrossRef] [Google Scholar]
68. Alves J. S. F., Marques J. L., Demarque D. P., et al. Involvement of isoorientin in the antidepressant
bioactivity of a flavonoid-rich extract from Passiflora edulis f. flavicarpa leaves. Revista Brasileira de
Farmacognosia. 2020;30:240–250. doi: 10.1007/s43450-020-00003-x. [CrossRef] [Google Scholar]
69. Rashno M., Ghaderi S., Nesari A., Khoesandi L., Farbood Y., Sarkaki A. Chrysin attenuates traumatic brain
injury-induced recognition memory decline, and anxiety/depression-like behaviors in rats: insights into
underlying mechanisms. Psychopharmacology. 2020;237:1607–1619. doi: 10.1007/s00213-020-05482-
3. [PubMed] [CrossRef] [Google Scholar]
70. Appel K., Rose T., Fiebich B., Kammler T., Hoffmann C., Weiss G. Modulation of the γ-aminobutyric acid
(GABA) system by Passiflora incarnata L. Phytotherapy Research. 2011;25:838–843.
doi: 10.1002/ptr.3352. https://onlinelibrary.wiley.com/doi/epdf/10.1002/ptr.3352. [PubMed]
[CrossRef] [Google Scholar]
71. Viola H., Wasowski C., Stein M. L., et al. Apigenin, a component of Matricaria recutita flowers, is a central
benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica. 1995;61:213–216. doi: 10.1055/s-
2006-958058. [PubMed] [CrossRef] [Google Scholar]
72. Vissiennona C., Nieber K., Kelber O., Butterweck V. Route of administration determines the anxiolytic
activity of the flavonols kaempferol, quercetin and myricetin—are they prodrugs? The Journal of Nutritional
Biochemistry. 2012;23:733–774. doi: 10.1016/j.jnutbio.2011.03.017. [PubMed] [CrossRef] [Google Scholar]
73. Braestrup C., Nielsen M., Olsen C. E. Urinary and brain β-carboline-3-carboxylates as potent inhibitors of
brain benzodiazepine receptors. Proceedings of the National Academy of Sciences of the United States of
America. 1980;77:2288–2292. doi: 10.1073/pnas.77.4.2288. [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
74. Bharate S. S., Mignani S., Vishwakarma R. A. Why are the majority of active compounds in the CNS
domain natural products? A critical analysis. Journal of Medicinal Chemistry. 2018;61:10345–10374.
doi: 10.1021/acs.jmedchem.7b01922. [PubMed] [CrossRef] [Google Scholar]
75. Salerno S., Settimo F., Taliani S., et al. Medicinal chemistry of indolylglyoxylamide GABA A/BzR high
affinity ligands: identification of novel anxiolytic/non sedative agents. Current Topics in Medicinal
Chemistry. 2012;12:286–311. doi: 10.2174/156802612799078847. [PubMed] [CrossRef] [Google Scholar]
76. Clayton T., Poe M. M., Rallapalli S., et al. A review of the updated pharmacophore for the alpha 5
GABA(A) benzodiazepine receptor model. International Journal of Medicinal Chemistry. 2015;2015:54.
doi: 10.1155/2015/430248.430248 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
77. Brazil, Ministry of Health. “Normative instruction n. 2./May 13, 2014,” Diário Oficial da União, Brasilia,
Section 1. Brasilia, Brazil: ANVISA; 2014. pp. 58–
15
61. http://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?
data=14/05/2014&jornal=1&pagina=58&totalArquivos=100. [Google Scholar]
79. Fierascu R. C., Fierascu I., Ortan A., Georgiew M. I., Sieniawska E. Innovative approaches for recovery of
phytoconstituents from medicinal/aromatic plants and biotechnological
production. Molecules. 2020;25(2):p. 309. doi: 10.3390/molecules25020309. [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
80. He S. M., Chan E., Zhou S. F. ADME Properties of herbal medicines in humans: evidence, challenges and
strategies. Current Pharmaceutical Design. 2011;17:357–407. doi: 10.2174/138161211795164194. [PubMed]
[CrossRef] [Google Scholar]
81. Huang C., Zheng C., Li Y., Wang Y., Lu A., Yang L. Systems pharmacology in drug discovery and
therapeutic insight for herbal medicines. Briefings in Bioinformatics. 2013;15:710–733.
doi: 10.1093/bib/bbt035. [PubMed] [CrossRef] [Google Scholar]
82. Sut S., Baldan V., Faggian M., Peron G., Dall’Acqua S. Nutraceuticals, a new challenge for medicinal
chemistry. Current Medicinal Chemistry. 2016;23:1–26.
doi: 10.2174/0929867323666160615104837. [PubMed] [CrossRef] [Google Scholar]
83. Rasool M., Malik A., Waquar S., et al. In-Silico characterization and in-vivo validation of Albizia saponin-
A, iso-orientin, and aalvadorin using a rat model of Alzheimer’s disease. Frontiers in
Pharmacology. 2018;9:99–113. doi: 10.3389/fphar.2018.00730. [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
84. Wang M., Firrman J., Liu L., Yam K. A review on flavonoid apigenin: dietary intake, ADME, antimicrobial
effects, and interactions with human gut microbiota. BioMed Research International. 2019;2019:18.
doi: 10.1155/2019/7010467.7010467 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
85. Mirza M. U., Ghori N.-Ul-H., Ikram N., Adil A. R., Manzoor S. Pharmacoinformatics approach for
investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors. Drug Design,
Development and Therapy. 2015;9:1825–1841. doi: 10.2147/dddt.s75886. [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
86. Abraham M. H. The factors that influence permeation across the blood–brain barrier. European Journal
of Medicinal Chemistry. 2004;39:235–240. doi: 10.1016/j.ejmech.2003.12.004. [PubMed] [CrossRef] [Google
Scholar]
87. Stamatovic S. M., Keep R. F., Andjelkovic A. V. Brain endothelial cell-cell junctions: how to “open” the
blood brain barrier. Current Neuropharmacology. 2008;6:179–192.
doi: 10.2174/157015908785777210. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
88. Ancuceanu R., Dinu M., Dinu-Pirvu C., Anuta V., Negulescu V. Pharmacokinetics of B-ring unsubstituted
flavones. Pharmaceutics. 2019;11:p. 370. doi: 10.3390/pharmaceutics11080370. [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
89. Noh K., Oh D. G., Nepal M. R., et al. Pharmacokinetic interaction of chrysin with caffeine in
rats. Biomolecules & Therapeutics. 2016;24(4):446–452. doi: 10.4062/biomolther.2015.197. [PMC free
article] [PubMed] [CrossRef] [Google Scholar]
90. Cicero A. F. G., Colletti A. Nutraceuticals Active on Central Nervous System. Cham, Switzerland: Springer
International Publishing AG; 2018. Handbook of Nutraceuticals for Chemical Use; pp. 1–23.
[CrossRef] [Google Scholar]
91. Mori A., Hasegawa K., Murasaki M., et al. Clinical evaluation of Passiflamin (Passiflora extract) on
neurosis—multicenter double blind study in comparison with mexazolam. Clinical Evaluation. 1993;21:383–
440. [Google Scholar]
16
92. Miyasaka L. S., Atallah Á. N., Soares B. “Passiflora for Anxiety Disorder,” Cochrane Database of Systematic
Reviews Issue 1. Art. No CD004518. 2007. Cochrane, London,
UK. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004518.pub2/full. [PubMed] [Google
Scholar]
93. Akhondzadeh S., Naghavi H. R., Vazirian M., Shayeganpour A., Khani M. Passionflower in the treatment
of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical
Pharmacy and Therapeutics. 2001;26:363–367. doi: 10.1046/j.1365-2710.2001.00367.x. [PubMed]
[CrossRef] [Google Scholar]
94. Akhondzadeh S., Kashani L., Mobaseri M., Hosseini S. H., Nikzad S., Khani M. Passionflower in the
treatment of opiates withdrawal: a double-blind randomized controlled trial. Journal of Clinical Pharmacy
and Therapeutics. 2001;26:369–373. doi: 10.1046/j.1365-2710.2001.00366.x. [PubMed] [CrossRef] [Google
Scholar]
95. Movafegh A., Alizadeh R., Hajimohamadi F., Esfehani F., Nejatfar M. Preoperative oral Passiflora
incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled
study. Anesthesis & Analgesia. 2008;106:1728–1732. doi: 10.1213/ane.0b013e318172c3f9. [PubMed]
[CrossRef] [Google Scholar]
96. Aslanargun P., Cuvas O., Dikmen B., Aslan E., Yuksel M. U. Passiflora incarnata Linneaus as an anxiolytic
before spinal anesthesia. Journal of Anesthesia. 2012;26:39–44. doi: 10.1007/s00540-011-1265-6. [PubMed]
[CrossRef] [Google Scholar]
97. Dantas L. P., Oliveira-Ribeiro A., Almeida-Souza L. M., Groppo F. C. Effects of Passiflora incarnata and
midazolam for control of anxiety in patients undergoing dental extraction. Medicina Oral, Patologia Oral y
Cirurgia Bucal. 2017;22:e95–101. doi: 10.4317/medoral.21140. [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
99. Brazil, Presidency of the Republic. “Law No. 9.279/May 14, 1996,” Diário Oficial da União, Brasilia,
Section 1. Brasília, Brazil: National Congress; 1996. p. p.
8353. http://www.planalto.gov.br/ccivil_03/leis/L9279.htm. [Google Scholar]
100. Brazil, Presidency of the Republic. “Decree No 5.813/June 22, 2006,” Diário Oficial da União, Brasilia,
Section 1. Brasília, Brazil: National Congress; 2006. p. p. 2. http://www.planalto.gov.br/ccivil_03/_ato2004-
2006/2006/decreto/d5813.htm. [Google Scholar]
102. Brazil, Presidency of the Republic. “Law No 9.782/January 26, 1999,” Diário Oficial da União, Brasilia,
Section 1. Brasília, Brazil: National Congress; 1999. p. p.
1. http://www.anvisa.gov.br/legis/consolidada/lei_9782_99.pdf. [Google Scholar]
103. Brazil, Ministry of Health. “RDC No 38/June 18, 2014,” Diário Oficial da União, Brasilia, Section
1. Brasilia, Brazil: ANVISA; 2014. pp. 58–
61. http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2014/rdc0038_18_06_2014.pdf http://
bvsms.saude.gov.br/bvs/saudelegis/anvisa/2014/rdc0038_18_06_2014.pdf http://bvsms.saude.gov.br/bvs/
saudelegis/anvisa/2014/rdc0038_18_06_2014.pdf. [Google Scholar]
104. Brazil, Ministry of Health. “RDC 66/November 26, 2014,” Diário Oficial da União, Brasilia, Section
1. Brasilia, Brazil: ANVISA; 2014. pp. 46–47. http://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?
jornal=1&pagina=46&data=27/11/2014. [Google Scholar]
105. Brazil, Ministry of Health. “RDC 105/August 31, 2016,” Diário Oficial da União, Brasilia, Section
1. Brasilia, Brazil: ANVISA; 2016. pp. 47–48. http://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?
jornal=1&pagina=47&data=01/09/2016. [Google Scholar]
17
106. United States. Patent full-text databases. 2019. http://patft.uspto.gov/netahtml/PTO/search-
bool.html US Patent.
18